Filling the Void in Drug Delivery

Eupraxia Pharmaceuticals has developed a novel platform that enables us to modulate drug release with precision.  This ability allows us to tailor the profiles of proven drugs to improve safety, duration and efficacy.

Our disruptive technology encapsulates pharmaceutical microparticles in a customizable polymer shell that can extend drug release from days to months.   Starting with osteoarthritis (a degenerative joint disease), we are advancing a portfolio of drug candidates tailored to specific treatment needs in the areas of osteoarthritis, chronic pain, post-surgical pain and anti-infectives.

Our lead product candidate, EP-104IAR, is a locally delivered, sustained-release, non-opioid treatment for pain related to osteoarthritis.